<DOC>
	<DOC>NCT01175330</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy of Polyunsaturated Fatty Acid for the prevention of Atrial Fibrillation and anti-inflammatory effects in patients after CABG surgery</brief_summary>
	<brief_title>Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
	<criteria>Elective CABG surgery. Signed, documented informed consent prior to admission to the study. Unstable angina, requiring intervention or CABG &lt;24 hrs after screening. Decompensated congestive heart failure. Chronic, persistent, paroxysmal atrial fibrillation. Uncorrected significant valvular heart disease Known hypersensitivity to the study drug Left ventricular dysfunction (ejection fraction &lt;35%) Use of antiarrhythmic drugs other than beta blockers Noncardiac illness with a life expectancy of less than 1 year Bleeding diathesis or history of coagulopathy Significant renal and liver insufficiency Significant thyroid, pulmonary disease Uncontrolled diabetes mellitus Patients on antiarrhythmic drugs Patients with pacemaker Patients unable to provide/sign informed consent. Patients currently taking marine based omegathree fish oil supplements. Disturbances in lipid metabolism, serum triglyceride value &gt;3 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Omega-3 fatty acid</keyword>
	<keyword>Ischemic Heart Disease</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Subcutaneous cardiac monitoring</keyword>
</DOC>